2-Methyl-3-(3,7,11,15,19,23,27,31-octamethyldotriaconta-2,6,10,14,18,22,26,30-octaenyl)naphthalene-1,4-dione | 523-38-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-Methyl-3-(3,7,11,15,19,23,27,31-octamethyldotriaconta-2,6,10,14,18,22,26,30-octaenyl)naphthalene-1,4-dione
• CAS: 523-38-6
• 化学式: C₅₁H₇₂O₂
• 分子量: 717.1
• InChiKey: LXKDFTDVRVLXFY-UHFFFAOYSA-N

物化性质

• 沸点：
  764.8±60.0 °C(Predicted)
• 密度：
  0.955±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  16.4
• 重原子数：
  53
• 可旋转键数：
  23
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.49
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• TREATMENT OF MITOCHONDRIAL DISEASES WITH VITAMIN K
  申请人：Jankowski Orion D.

  公开号：US20140031432A1

  公开（公告）日：2014-01-30

  Methods of treating, preventing or suppressing symptoms associated with mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), dominant optic atrophy (DOA); mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Leigh syndrome or Kearns-Sayre Syndrome (KSS) with vitamin K are disclosed.
• [EN] ADJUNCTIVE THERAPY FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS WITH QUINONES AND NAPHTHOQUINONES<br/>[FR] TRAITEMENT ADJUVANT AU TRAITEMENT DES MALADIES MITOCHONDRIALES AVEC DES QUINONES ET DES NAPHTOQUINONES
  申请人：EDISON PHARMACEUTICALS INC

  公开号：WO2012170773A1

  公开（公告）日：2012-12-13

  The present invention relates to an adjunctive therapy for the treatment of mitochondrial disorders comprising the administration of an effective amount of one or more quinones and one or more naphthoquinones to a patient in need therof. The present invention also relates to an adjunctive therapy for the treatment of mitochondrial disorders comprising the administration of an effective amount of one or more quinones or their reduced form hydroquinones and one or more naphthoquinones or their reduced form naphthohydroquinones to a patient in need therof.